Allurion Technologies received a patent for its enhanced, next-generation gastric balloon technology, specifically for its improved valve system. This new patent adds to Allurion’s existing intellectual property, totaling 20 patents in the U.S. and 59 globally. The patented technology focuses on the precision of the balloon’s valve system, a critical component of the Allurion Program, a weight-loss platform combining the swallowable gastric balloon with a virtual care suite.
This patent is important because it strengthens Allurion’s competitive position in the weight-loss market. It provides extended intellectual property protection for a key element of its technology, potentially deterring competitors and solidifying the company’s market advantage. This protection could translate into greater market share and increased revenue potential, particularly as the demand for effective, less invasive weight-loss solutions grows. The enhanced valve system may also lead to improved patient outcomes, potentially increasing the efficacy and safety of the Allurion Gastric Balloon.
This patent offers protection through July 2039. It covers an enhanced version of Allurion’s existing swallowable gastric balloon, focusing on the precision of the valve system controlling balloon opening. The Allurion Program incorporates a virtual care suite, including a mobile app and connected scale, to support patients throughout their weight-loss journey. Patients using the Allurion Program typically experience 10-15% total body weight loss, with some studies showing increased muscle mass.
This patent reinforces Allurion’s commitment to innovation in the obesity treatment space. The extended patent protection secures the company’s investment in research and development, allowing for continued exploration of advancements in its gastric balloon technology. This innovation may lead to further refinements in the device’s design, functionality, and patient experience, ultimately strengthening Allurion’s long-term market position and contributing to the development of more effective obesity solutions.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
